Crossmark

Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial

Crossref DOI link: https://doi.org/10.1038/s41591-024-02989-6

Published Online: 2024-06-01

Published Print: 2024-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Feng https://orcid.org/0000-0001-7668-9674
Shen, Lin

Guo, Weijian

Liu, Tianshu https://orcid.org/0000-0002-8604-6311
Li, Jin https://orcid.org/0000-0003-0099-874X
Qin, Shukui

Bai, Yuxian

Chen, Zhendong

Wang, Jufeng

Pan, Yueyin https://orcid.org/0000-0003-0532-5368
Shu, Yongqian

Zhao, Fuyou

Cheng, Ying

Ye, Feng

Gu, Kangsheng

Zhang, Tao

Pan, Hongming

Zhong, Haijun

Zhou, Fuxiang

Qin, Yanru

Yang, Lei

Mao, Weidong

Li, Qiu

Dai, Wenxiang

Li, Wei

Wang, Shubin

Tang, Yong

Ma, Dong

Yin, Xianli

Deng, Yanhong

Yuan, Ying https://orcid.org/0000-0002-3922-9553
Li, Man

Hu, Wenwei

Chen, Donghui

Li, Guoxin https://orcid.org/0000-0003-2773-7048
Liu, Qiqi

Tan, Panfeng

Fan, Songhua

Shi, Michael

Su, Weiguo

Xu, Rui-Hua https://orcid.org/0000-0001-9771-8534
License Information

Text and Data Mining valid from 2024-06-01

Version of Record valid from 2024-06-01
More Information

Article History

Received: 5 March 2024

Accepted: 10 April 2024

First Online: 1 June 2024

Competing interests

: Q.L., P.T., S.F., M.S. and W.S. are employees of HUTCHMED Limited. All other authors declare no competing interests.

Document is current

Any future updates will be listed below